John Carroll

Biography for John Carroll

John D. Carroll, Editor-in-Chief

John D. Carroll is a biotech analyst with 36 years of experience in journalism that’s taken him all over the world--and back again. Appointed editor of FierceBiotech in 2003, he has covered everything from city hall in Kansas City, KS, to biotech in London. He contributed stories from Central America and Ireland to the Dallas Morning News and Time and wrote for the Houston Press and a medley of other publications. He spent six years as editor and then publisher of the Dallas Business Journal, was publisher of Texas Business for a brief stint and early in his career was part of a big team of reporters and editors at the Kansas City Star & Times that investigated the deadly 1981 disaster at a local Hyatt Regency. The newspapers won a 1982 Pulitzer for their collective work. Carroll lives in Vermont and travels frequently. He can be reached at john@fiercemarkets.com. Follow @JohnCFierce on Twitter.

Articles by John Carroll

Inovio reports clinical success for cervical cancer vax

Inovio Pharmaceuticals says its DNA cervical cancer vaccine produced promising results in an early-stage study, with one dose group registering "unprecedented T-cell responses" for five out of six

NanoBio unveils promising data on next-gen vaccine

University of Michigan spin-off NanoBio has passed a major milestone, offering up an initial positive round of data from an early-stage human study of its next-generation nanoparticle flu vaccine.

Cloning a human virus offers clear vaccine target

Human cytomegalovirus is a clearly defined threat. At its worst the virus triggers congenital malformations in newborns, as well as lethal threats to transplant recipients and AIDS patients--two

Next-gen cancer vaccines take center stage

In the four months since Provenge won approval at the FDA, the R&D spotlight has turned a bright beam of light on new therapeutic cancer vaccines now in the pipeline. And William Chambers,

U.K. tallies losses on pandemic vaccine

U.K. officials say they essentially lost more than £200 million ($308.9 million) buying up excess quantities of swine flu vaccine and antiviral meds. About a third of that loss occurred because

Vaccine gives dangerous pneumococcus strains an opening

When a vaccine that guards against the most common causes of pneumococcal disease comes to the market, it's simultaneously creating fresh opportunities for strains not covered in the shot, scientists

Epidemiologists fear monkeypox outbreak could spread

An outbreak of monkeypox has hit Central Africa, raising fears among U.S. epidemiologists that the once rare variation of smallpox and cowpox could erupt as a lethal new threat if it undergoes fresh

Medicare's Provenge review comes into clearer focus

With billions in revenue at stake, every new twist and turn in the saga revolving around the rollout of Provenge gets put under the microscope. Any possibility of market restrictions, a fear raised

Bill Gates on vaccines: "Our investment is mind-blowing"

In a recent interview with Technology Review, billionaire philanthropist Bill Gates explains his vaccine development strategy, noting he has enough money to make a market where none exists naturally.

Will FDA reconsider hen vaccination program?

With the U.S. engaged in the biggest egg recall effort ever, the New York Times examines the FDA's recent decision that it would not require the vaccination of the country's chickens against